Oncotarget

Clinical Research Papers:

Leucine-rich alpha-2-glycoprotein-1, relevant with microvessel density, is an independent survival prognostic factor for stage III colorectal cancer patients: a retrospective analysis

De-Cong Sun, Yan Shi, Ling-Xiong Wang, Yao Lv, Quan-Li Han, Zhi-Kuan Wang and Guang-Hai Dai _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:66550-66558. https://doi.org/10.18632/oncotarget.16289

Metrics: PDF 591 views  |   HTML 874 views  |   ?  


Abstract

De-Cong Sun1, Yan Shi1, Ling-Xiong Wang1,2, Yao Lv1, Quan-Li Han1, Zhi-Kuan Wang1 and Guang-Hai Dai1

1 The Second Department of Oncology, Chinese PLA General Hospital, Beijing, China

2 Current Adress: Cancer Center Key Laboratory, Chinese PLA General Hospital, Beijing, China

Correspondence to:

Guang-Hai Dai, email:

Keywords: leucine-rich alpha-2-glycoprotein-1, microvessel density, stage III colorectal cancer, a retrospective analysis

Received: December 07, 2016 Accepted: March 09, 2017 Published: March 16, 2017

Abstract

Background: Leucine-rich alpha-2-glycoprotein-1 (encoded by LRG1) has been shown to be involved in multiple cancer progression and angiogenesis. LRG1 has been shown to be one of the five plasma proteins that can be used for colorectal cancer (CRC) diagnosis. The objective of the current study was to explore relationship between LRG1 protein expression and microvessel density (MVD) in stage III CRC. Methods: A single-center retrospective analysis of all stage III CRC who underwent surgery and adjuvant chemotherapy was carried out. LRG1 and CD34 were tested in tumor tissues by immunohistochemistry (IHC). Results: LRG1 protein expression was significantly associated with MVD (P <0.001) and other clinicopathological parameters, including T stage (P=0.028), differentiation (P=0.035) and vascular invasion (P=0.007). Cox multivariate regression analysis showed that LRG1 protein expression was an independent poor predictive factor for both disease-free and overall survival. Conclusion: LRG1 protein expression can be used as a prognostic marker for stage III CRC along with its use as a diagnostic marker for CRC in general.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16289